Research & Development in
Basel
261 companies in Research & Development based in Basel — name and year of registration from the commercial register.
50 of 261 companies
Bio-Rad Europe GmbH
Since 2017 · 101–500 empl.4.6(47)
Bio-Rad Europe GmbH is a company active in life science research and clinical diagnostics. It provides instruments, reagents, quality control solutions, and data tools for research, diagnostic testing, and laboratory workflows.
youEngineering AG
Since 2013 · 21–50 empl.4.9(14)
The core activity of youEngineering AG is the development of software, web design and mobile applications, as well as consulting services in these areas. The company offers agile software engineering and develops solutions using various programming languages and technologies.
Merian Iselin Forschung AG
Since 2021 · 21–50 empl.4.5(272)
Merian Iselin Forschung AG is a platform for academic, non-commercial and independent research aimed at strengthening patient-oriented outcome research. It focuses on orthopedics, urology and related areas, supports specific research projects and promotes scientific training.
Friedrich Miescher Institute for Biomedical Research
Since 2012 · 51–100 empl.4.9(12)
The Friedrich Miescher Institute for Biomedical Research (FMI) is a research institute focused on biomedical research. Its core activities include: * Basic research in the areas of Genome Regulation, Multicellular Systems, and Neurobiology * Application of technology platforms such as Structural Biology, Functional Genomics, Proteomics & Protein Analysis, Facility for Advanced Imaging and Microscopy, and C. elegans Facility * Education and career development through PhD and MD-PhD programs, postdoctoral activities, and teaching * Promotion of Equity, Diversity & Inclusion, as well as support for employees and alumni Thus, the FMI is a research institute that concentrates on exploring biomedical issues, employing a wide range of scientific disciplines and technologies.
Eumedica Pharmaceuticals AG
Since 1995 · 21–50 empl.4.6(5)
The core activity of Eumedica Pharmaceuticals AG is the development, manufacture and marketing of pharmaceuticals, particularly established products for rare and severe diseases. The company focuses on addressing critical unmet medical needs and offers a broad range of therapeutic solutions distributed in over 36 countries.
BAK Economics AG
Since 1987 · 21–50 empl.5.0(1)
The core activity of BAK Economics AG is the conduct of economic research and consulting. Specifically, this includes the creation of studies and analyses focusing on macroeconomic forecasts and scenarios, regional analyses and industry studies, impact analyses (Economic Footprint), as well as studies in the field of public finance. Furthermore, the company offers strategy support and impact analyses for businesses to examine and communicate their effects on the regional economy.
SpiroChem AG
Since 2011 · 101–500 empl.3.8(4)
The core activity of SpiroChem is the development and provision of services and solutions in the field of chemical research and development, particularly in drug development. This includes, among other things: Research and Development (R&D), Fully Integrated Services, Computational Chemistry, Artificial Intelligence (AI) and Machine Learning (ML), development of new active ingredients and medicines, method development and reference standards, as well as consulting and partnerships with industry experts. The company also offers specialized services such as protein degradation processes, antibody-drug conjugates (ADCs) and other bio-conjugates.
Institut für molekulare und klinische Ophthalmologie Basel
Since 2017 · 11–20 empl.4.8(5)
The company IOB (Institute of Molecular and Clinical Ophthalmology Basel) is dedicated to the research and treatment of eye diseases. The core activity of the company includes the conduct of molecular and clinical research in the field of ophthalmology, with the aim of developing new therapies and treatment methods for eye diseases. This also includes the conduct of clinical trials and collaboration with partners from science and industry.
Verein Energie Zukunft Schweiz
Since 2006 · 11–20 empl.4.8(4)
Verein Energie Zukunft Schweiz develops and implements solutions for renewable energy, including biogas, photovoltaics, heating and e-mobility. The association supports utilities, real estate professionals, companies, public authorities and other client groups in delivering energy transition projects.
Alira Health AG
Since 2011 · 51–100 empl.5.0(2)
The company provides consulting services to companies in the healthcare and life sciences sector. The core activities include: Strategic consulting and management consulting for healthcare companies, Regulatory consulting and support for the approval of medicines and medical devices, Clinical research and development, including biometrics and CMC (Chemistry, Manufacturing and Controls), Market access and patient engagement, Transaction consulting and support for mergers and acquisitions, ESG strategy and sustainability consulting, Research and development of solutions for specific health problems, such as wound care. The company supports its customers in developing strategies, implementing projects, and overcoming regulatory hurdles to ultimately improve healthcare and promote patient well-being.
Stiftung Europainstitut Basel
Since 1993 · 21–50 empl.
The company is a research institute that deals with European and global issues, particularly European law. It offers study and research programs and regularly publishes annual reports and other publications. The institute also has an administrative function and offers further education courses. It is part of the University of Basel and has close ties to international networks.
ecos AG
Since 1996 · 11–20 empl.
The core activity of ecos is to advise and support companies, organizations and authorities in the implementation of sustainability strategies and solutions. This includes, among other things, the development of climate goals and decarbonization strategies, the identification of climate risks and opportunities, the accounting of greenhouse gas emissions, the integration of sustainability into internal processes, and the communication of sustainability performance. The company also offers training, workshops and consulting services in the areas of circular economy, sustainable textiles and regulatory compliance.
PreClinical Safety (PCS) Consultants Ltd
Since 1996 · 1–10 empl.
The core activity of PreClinical Safety (PCS) Consultants Ltd is to provide consulting and services in the field of drug development, particularly in the preclinical phase. This includes, among others: risk management and assessment, quality assurance and Good Laboratory Practice (GLP), pharmacokinetics and pharmacodynamics, drug development and testing, clinical pharmacology and studies, and regulatory services, including the preparation of regulatory documents such as IBs, INDs, Briefing Books and CTDs. The company offers these services to support customers in decision-making and implementation of drug development projects.
Denkstatt Sàrl
Since 1996 · 21–50 empl.
Denkstatt Sàrl is an interdisciplinary team focused on transformative urban development and planning support. Its work covers existing-building transformation, adaptive reuse, participation processes, open-space development, urban climate, and sustainable organisational and communication models.
Elanco Tiergesundheit AG
Since 1997 · 21–50 empl.
The core activity of Elanco is the development and manufacture of animal health medicines and products that improve the health, well-being and performance of animals, as well as providing services and solutions for animal health.
Medpace Switzerland AG
Since 1998 · 11–20 empl.
Medpace Switzerland AG is a contract research organization (CRO) that provides services for clinical development of medical therapeutics. The company supports sponsors with study planning, clinical trial management, regulatory services, data management, and laboratory and imaging services.
McArthur and Associates GmbH
Since 2001 · 11–20 empl.
The core activity of McArthur and Associates GmbH is to advise and support companies, venture capital organizations, and academic groups in the biopharmaceutical industry in the development of drugs and early clinical trials. This includes services such as product or project evaluation, in vitro and in vivo biology, medical writing, competitive analysis, toxicology and biomarkers, medicinal chemistry and formulation, as well as graphic design and scientific communication.
Life Imaging Services GmbH
Since 2007 · 1–10 empl.
The core activity of Life Imaging Services GmbH is the development, manufacture and distribution of medical imaging devices and related services.
Edelweiss Connect GmbH
Since 2008 · 11–20 empl.
The core activity of Edelweiss Connect is to provide services in the field of risk management and data management, particularly in the pharmaceutical industry and related areas. This includes, among other things: document management and analysis, risk assessment and management, research and development in collaboration with industry companies, academic institutions and regulatory authorities, and the development of solutions for complex business problems through the use of expert knowledge and collaborative approaches. The company focuses on providing innovative solutions and services to support the decision-making and success of its customers.
BioVersys AG
Since 2008 · 21–50 empl.
The core activity of Bioversys AG is the development and manufacture of pharmaceuticals, particularly in the field of antibiotic research and the development of therapeutics for various diseases. The company is engaged in the research and development of small molecules, peptides and therapeutic polymers and has experts in the fields of medicinal chemistry, CMC (Chemistry, Manufacturing, Control) and biotechnology on its team.
PAREXEL International (CH) AG
Since 2008 · 1–10 empl.
PAREXEL International (CH) AG is a clinical research organization (CRO) that provides services for pharmaceutical and biopharmaceutical clinical development. Services include Phase I–IV clinical trial management, regulatory strategy and submissions, drug safety and pharmacovigilance, real‑world evidence and market access support, as well as clinical trial supply and medical communications.
SFL Regulatory Affairs & Scientific Communication GmbH
Since 2009 · 21–50 empl.
The core activity of Veristat is the conduct and support of clinical trials and the development of medicinal products, particularly in the areas of oncology, neurology, endocrinology, infectious diseases and cardiovascular diseases. The company offers services such as clinical trial planning, execution and monitoring, statistical analysis, regulatory consulting, market access and reimbursement, pharmacovigilance, medical communication and supply chain management.
St. Clara Forschung AG
Since 2010 · 21–50 empl.
The company's core activity is academic, non-commercial, independent, and free research in the field of medicine, particularly in the areas of: metabolic and gastroenterological research, medical and medical-oncological research, visceral surgical research, and cancer research/general research. The company conducts high-level clinical research and maintains international collaborations to carry out national and international research projects.
FGen AG
Since 2011 · 11–20 empl.
The core activity of Ginkgo Bioworks is the development and provision of research and development (R&D) solutions for various industries, including agriculture, biopharmaceuticals, biosecurity, government, and industrial biotechnology. The company offers a platform with various tools and services, including artificial intelligence (AI), laboratory automation, data analysis and generation, to accelerate customers' research and development. Ginkgo Bioworks works closely with its partners to develop customized R&D solutions and offer products and services tailored to the specific needs of its customers.
Ironwood Pharmaceuticals GmbH
Since 2012 · 21–50 empl.
The core activity of Ironwood is the development and manufacture of pharmaceutical products, particularly the research and development of therapeutics for various diseases and health conditions.
NBE-Therapeutics AG
Since 2012 · 21–50 empl.
The core activity of NBE-Therapeutics AG is the development and research of therapeutics, particularly in the field of cancer treatment. The company focuses on the development of antibody-drug conjugates (ADCs) and other therapeutics targeting the fight against cancer cells.
Indivi AG
Since 2012 · 51–100 empl.
The core activity of Indivi is the development and integration of innovative digital solutions for the research and treatment of neuroimmunological and neurodegenerative diseases, particularly multiple sclerosis. The company works closely with the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) to advance the development of precision medicine and personalized treatment approaches.
MentAge GmbH
Since 2013 · 1–10 empl.
MentAge GmbH provides consulting, supervision and courses, as well as clinical services in the fields of dementia and geriatric medicine. The website also refers to expert reports, support for care facilities and dementia-friendly hospital concepts.
Amyra Biotech AG
Since 2013 · 1–10 empl.
The core activity of AMYRA Biotech is the development and research of Brush Border Enzyme Supplementation Technology (BBEST), particularly for the treatment of general health and nutrition issues, food intolerances and gastrointestinal diseases through the supplementation of enzymes found in the small intestine mucosa.
Caris Life Sciences Switzerland Holdings GmbH
Since 2013 · 1–10 empl.
Caris Life Sciences Switzerland Holdings GmbH provides comprehensive molecular profiling, protein analysis and AI-based interpretation to deliver therapy-relevant information for patients, physicians and biopharma partners. Its offerings include tissue- and blood-based tests (for example MI Profile and Caris Assure), molecular tumor board services, and multimodal molecular and clinical data and analysis tools for research and clinical development.
LYO-X AG
Since 2014 · 1–10 empl.
The core activity of LYO-X AG is modeling and simulation as well as systems pharmacology for the preclinical and clinical development of biotherapeutics.
NOUSCOM AG
Since 2015 · 21–50 empl.
The core activity of Nouscom is the development of cancer vaccines, in particular neoantigen-based cancer vaccines for tumors with microsatellite instability.
psHolix AG
Since 2015 · 1–10 empl.
psHolix AG develops and patents pseudo-holographic display technology (Super Multiview) that enables multiple viewers to see true 3D without glasses while simultaneously displaying 2D content on the same screen. The technology is offered for sectors such as automotive, defense, aviation, gaming, consumer electronics, medical and digital signage.
propatient Forschungsstiftung Universitätsspital Basel
Since 2015 · 11–20 empl.
The company's core activity is the promotion of research projects in the field of medicine and life sciences, particularly in collaboration with the University Hospital Basel. The foundation supports scientific projects and researchers through financial resources and provides a platform for the exchange of ideas and results. The core activity also includes communication with various target groups, such as patients, employees of the University Hospital and the general public, to inform them about the activities and results of the foundation.
IntiQuan AG
Since 2015 · 11–20 empl.
The core activity of IntiQuan AG is the provision of services in the field of pharmacometrics and strategic consulting for the pharmaceutical industry. The company offers Model-informed Drug Development (MIDD) solutions that enable the support of drug development through the application of modeling and simulation methods. The services include, among other things, the performance of pharmacokinetic and pharmacodynamic modeling, the analysis of clinical data, and the development of strategies for the market launch of drugs.
TargImmune Therapeutics AG
Since 2016 · 1–10 empl.
The core activity of TargImmune Therapeutics AG is the development and research of oncological compounds and the development of a modular, synthetic, targeted platform technology for nucleic acid therapy. In particular, the company focuses on the development of targeted apoptosis and immunomodulators (TAIMs) that use synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly to the target. The goal is to selectively destroy cancer cells by mimicking natural processes.
International Foundation for Patient Blood Management (IFPBM)
Since 2016 · 21–50 empl.
The company's core activity is medical research and education in the field of surgery, particularly in the areas of visceral surgery, vascular surgery, and patient blood management. The company also offers training programs and courses for physicians and surgeons and is involved in the development of educational materials and methods.
epibreed AG
Since 2016 · 1–10 empl.
epibreed AG provides crop-breeding and epigenetics services and has developed the patented TEgenesis® method, which mobilizes transposable elements in seedlings or clones to accelerate natural adaptation processes. Services listed on the website include rapid breeding for abiotic and biotic stress tolerance, increasing phenotypic diversity, generation of inducible traits, gene discovery, and genome-wide DNA methylation analysis.
Nursing Science & Care GmbH
Since 2016 · 11–20 empl.
The core activity of Nursing Science & Care GmbH is the conduct of research, training and consulting in the field of nursing science, particularly in the area of ambulatory care and support for older people. The activities include the creation of scientifically based position papers and expert opinions, the implementation of research projects, the consulting of practice partners and researchers, as well as the training and support of doctoral students in nursing science.
Urovant Sciences GmbH
Since 2016 · 1–10 empl.
Urovant Sciences GmbH is a pharmaceutical company focused on research, development and commercialization of therapies in urology, including treatments for overactive bladder such as Vibegron.
Scailyte AG
Since 2017 · 11–20 empl.
The core activity of Scailyte is the development and application of digital solutions for single-cell analysis, particularly in the field of cell therapy. The company focuses on the development of biomarkers and the application of artificial intelligence and machine learning in single-cell biology. Scailyte provides solutions for the pharmaceutical, biotech, and clinical research industries and develops products such as ScaiVision, a system for single-cell analysis.
Novaremed AG
Since 2017 · 11–20 empl.
Novaremed AG develops non-opioid pharmaceutical therapies for the treatment of chronic neuropathic pain and peripheral neuropathies. Its lead candidate, nispomeben (NRD.E1), is an orally active small molecule in clinical development and is being evaluated in an NIH-supported Phase 2b trial for painful diabetic peripheral neuropathy with FDA Fast Track designation; an earlier-stage candidate, MP-101, targets prevention of chemotherapy-induced peripheral neuropathy.
Immunovant Sciences GmbH
Since 2018 · 11–20 empl.
Immunovant Sciences GmbH is a clinical-stage immunology company developing anti‑FcRn therapies, including IMVT‑1402 and batoclimab, to reduce pathogenic IgG autoantibodies in autoimmune diseases. The product candidates are described as fully human monoclonal antibodies intended for subcutaneous administration with dosing that may be tailored to disease stage and severity.
Prosalix AG
Since 2018 · 1–10 empl.
The core activity of Prosalix AG is the development and research of medical products, in particular citrate-based therapies, for the treatment of kidney and metabolic diseases. The company focuses on developing innovative solutions for nephrology, urology and endocrinology, with the goal of improving the quality of life for patients.
Synendos Therapeutics AG
Since 2019 · 21–50 empl.
The core activity of Synendos Therapeutics AG is the development of pharmaceuticals, particularly the research and development of active ingredients and medicines in various therapeutic areas, including clinical trials and approval. The company focuses on the development of medicines for various diseases, including neurological disorders, and offers services in the fields of medicinal chemistry, pharmacology, clinical research and development.
Laevoroc Medical AG
Since 2019 · 21–50 empl.
The core activity of Laevoroc Oncology AG is the development and research of cancer immunotherapies, particularly the development of next-generation, game-changing immune-oncology therapies for the treatment of cancer, including brain tumors and hematological malignancies.
VectivBio AG
Since 2019 · 1–10 empl.
VectivBio AG is a company active in gastrointestinal health. It focuses on the development of therapies and medicines for digestive diseases, with activities centered on research, development, and a related product pipeline.
AlphaMeld GmbH
Since 2019 · 11–20 empl.
AlphaMeld GmbH provides AI-driven platforms and services to support drug discovery and development. The AlphaMeld platform integrates biological, chemical and clinical data for target identification, indication optimization, drug design, mechanism-of-action analysis, biomarker discovery and clinical-trial strategy and study design, and includes a generative assistant (ChatAlphaMeld) for user interaction.
SOTIO Biotech AG
Since 2019 · 101–500 empl.
The core activity of SOTIO is the development and research of oncological therapies, particularly in the field of biologics, such as antibody-drug conjugates (ADCs), immunocytokines and cell therapies. The company focuses on the development of drugs for the treatment of cancer and has built a pipeline of oncological programs driven by strategic licensing, M&A and internal discovery efforts.
PharmaTrail AG
Since 2020 · 11–20 empl.
The core activity of PharmaTrail AG is the development and provision of software solutions for clinical trials, particularly in the areas of patient consent (eConsent), electronic patient-reported outcomes (ePRO/eCOA) and electronic data capture (EDC). The company focuses on integrating blockchain technology into clinical trials to enhance the integrity and transparency of data.
Research & Development in Basel
Research & Development in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Largest places
Riehen15Research & Development in other places
By canton